Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.

Yasuhiro KatoGou YamamotoYasutaka WatanabeYuki YamaneHideaki MizutaniFutoshi KurimotoMasahiro SeikeAkihiko GemmaKiwamu AkagiHiroshi Sakai

Published in: International journal of clinical oncology (2021)

Our results indicated that patients with NSCLCs harboring MET exon 14 mutations presented with a high rate of positive PD-L1 expression. ICI treatment showed a high ORR and long-term efficacy for NSCLCs harboring MET exon 14 mutations. Variants of MET exon 14 splice-site mutations may be associated with ICI response.

Keyphrases

tyrosine kinase
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
gene expression
patient reported outcomes
smoking cessation
patient reported